Summary of infections
| Variable . | No. of episodes . | No. of patients with ≥1 episode/no. at risk . | % . | Median days to infection (range) . |
|---|---|---|---|---|
| Any infection type* | 143 | 65/96 | 68 | 48 (1-180) |
| Viral* | 28 | 26/96 | 27 | 71.5 (1-172) |
| Fungal | 19 | 17/96 | 18 | 66 (3-180) |
| Bacterial | 96 | 57/96 | 59 | 44.5 (1-180) |
| CMV viremia† | 27 | 27/53‡ | 51 | 41 (9-131) |
| Hemorrhagic cystitis | 19 | 19/96 | 20 | 24 (4-141) |
| Variable . | No. of episodes . | No. of patients with ≥1 episode/no. at risk . | % . | Median days to infection (range) . |
|---|---|---|---|---|
| Any infection type* | 143 | 65/96 | 68 | 48 (1-180) |
| Viral* | 28 | 26/96 | 27 | 71.5 (1-172) |
| Fungal | 19 | 17/96 | 18 | 66 (3-180) |
| Bacterial | 96 | 57/96 | 59 | 44.5 (1-180) |
| CMV viremia† | 27 | 27/53‡ | 51 | 41 (9-131) |
| Hemorrhagic cystitis | 19 | 19/96 | 20 | 24 (4-141) |
Does not include CMV or urine BK/adenovirus.
CMV viremia defined as >150 copies/mL on PCR.
CMV at-risk defined as donor CMV-positive, recipient CMV-positive, or both donor and recipient positive during pre-BMT evaluation, and includes 1 patient who was neither donor nor recipient positive but had CMV viremia.